Key facts
- Atlas Molecular Pharma’s last known valuation is $4.6M (Oct 2023).
- It has raised $8.1M; the latest was Later Stage VC ($3.5M) in Jan 2026.
- Notable investors include INNVIERTE SICC, Inveready Asset Management, CDTI Innvierte, Arquimea Group, Center for Industrial Technological Development — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Atlas Molecular Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Atlas Molecular Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Atlas Molecular Pharma
Developer of therapeutic drugs designed to treat rare diseases. The company specializes in the identification of molecules or drugs that provide stability to proteins whose dysfunction is responsible for the development of rare diseases, enabling medical practitioners to improve the quality of their patients' lives cost-effectively.
- Sector
- Healthcare
- HQ
- Derio, Spain
- Founded
- 2015
- Employees
- 8
- Website
- atlasmolecularpharma.com/
- Ownership
- Privately Held (backing)
Atlas Molecular Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Atlas Molecular Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Atlas Molecular Pharma in its N-PORT filings yet. We sweep new filings monthly.